PDS Biotechnology Corporation Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results

Published: 2025-07-10 09:06:26 ET PDSB

Published on 07/10/2025 at 09:06

PDS Biotechnology Corporation announced patient recruitment has been completed in Stage 1 of a clinical trial of the Company's PDS01ADC therapeutic administered systemically in combination with floxuridine (FUDR) administered by hepatic artery infusion pump (HAIP) for patients with metastatic colorectal cancer (NCT05286814), led by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH). The study met the pre-set RECIST v1.1 criteria for expansion into Stage 2 of the study. The trial is an open label, single center, non-randomized Phase 2 study with three cohorts: metastatic colorectal Cancer cancer, cholangiocarcinoma, and adrenocortical cancer.

According to the American Cancer Society, colorectal cancer is the second leading cause of cancer-related deaths in the U.S.